Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Pasi A. Jänne, Yi‐Long Wu et al.|New England Journal of Medicine|2013Cited by 3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung CancerBenjamin Solomon, Fiona Blackhall, Tony Mok et al.|New England Journal of Medicine|2014Cited by 3.2k
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor CrizotinibDaniel B. Costa, Keith D. Wilner|Journal of Clinical Oncology|2011Cited by 590
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Paul K. Paik, Jeffrey W. Clark et al.|Nature Medicine|2020Cited by 393
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced CancersPatricia LoRusso, Alejandro D. Ricart, John J. Rinehart et al.|Clinical Cancer Research|2010Cited by 250